Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure

What Was Tested

The paper reports a study of Insulin Lispro and NPH Insulin (isophane), published as a randomized controlled trial.

The main aim of treatment of type 2 diabetic patients is to control plasma glucose and HbA1c levels.

In this study, the researchers aimed to assess the effects of three different insulin regimens (group I: lispro insulin + NPH insulin, group II: lispro insulin + metformin and group III: regular insulin + NPH insulin) on overall glycaemic control and metabolic parameters in type 2 diabetic patients with secondary oral anti-diabetic drug failure.

Who Took Part

The study group was 2 patients.

PubMed indexes the participants as adults, middle-aged adults and older adults.

Sixty type 2 diabetic patients with secondary OAD failure were randomly allocated into three different treatment groups equally.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Insulin Lispro and who got the comparison, which limits bias.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin and Insulin Lispro.

What This Means in Plain Language

The paper is a randomized study of Insulin Lispro and NPH Insulin (isophane) in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Lispro compound page and the NPH Insulin (isophane) compound page, all human trials.